<< Back to News

System Formulary Update
Fidaxomicin Tablets and Suspension

Situation

The System P&T Committee reviewed fidaxomicin tablets and oral suspension for formulary addition in January 2022.

Background

The following medications were reviewed by the System P&T Committee:

• Fidaxomicin 200 mg tablets
• Fidaxomicin 40 mg/mL oral suspension

Fidaxomicin is a macrolide antibiotic indicated for the treatment of clostridioides difficile-associated diarrhea in adults and pediatrics ≥6 months of age. It is an alternative to oral vancomycin for patients with C. diff infection. See additional information in the package insert.

Assessment/Recommendations

System P&T voted to APPROVE the addition of the following products to the UNC Health System Drug Formulary:

• Fidaxomicin 200 mg tablet
• Fidaxomicin 40 mg/mL oral suspension

Both products will be RESTRICTED at the System-level to the following:

• Limited to 10 equivalent days of therapy (ie, 20 doses)
• Short-term treatment only (ie, cannot be used for long-term prophylaxis or suppression)

Additional site-specific restrictions may apply.

Formulary/Epic changes will Go-Live on Tuesday, March 22, 2022